Product Information
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is a generic product labeled by Cipla USA Inc., priced at $0.6002 per EA under NDC 69097074102. Its NADAC has been published 150 times since Dec 22, 2021.
FDA first approved this application on Apr 2, 2021.
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATEStrength
200; 300 mg/1; mg/1
Manufacturer
Cipla USA Inc.NDC
69097074102
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
10/23/2024
Active Ingredients
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA090958FDA Approved
4/2/2021
On Market Since
11/1/2021
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has been published 150 times since Dec 22, 2021, and over the history we have for it it has declined 30.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6002 per EA |
|---|---|
| All-time high | $0.8681 (Jan 12, 2022) |
| All-time low | $0.4258 (May 22, 2024) |
| Median price | $0.5846 |
| Average price | $0.6016 |
| Largest weekly change | +37.3% (Jun 19, 2024) |
| Weeks tracked | 150 |
| Tracking since | Dec 22, 2021 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+1.8%
5Y
N/A
All
-30.9%
Last surveyed Oct 30, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, manufactured by Cipla USA Inc., is $0.6002 per EA (NDC 69097074102), effective Oct 30, 2024.
How has the price of EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has declined 30.9%. It has been tracked across 150 weekly CMS publications since Dec 22, 2021.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Since Dec 22, 2021, the NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB has ranged from a low of $0.4258 (May 22, 2024) to a high of $0.8681 (Jan 12, 2022), with a median of $0.5846 per EA.
Are there cheaper alternatives to EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, is $0.5694 per EA — about 5% below EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB.
Who manufactures EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB?
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB (NDC 69097074102) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.